Clinical Evidence: What the Trials Actually Show
Weight Loss Results: Wegovy 1.7mg vs Mounjaro Clinical Evidence
When comparing 1.7mg Wegovy to Mounjaro weight loss results, clinical trial data provides the most reliable evidence. In the landmark STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks (Wilding et al., NEJM, 2021). The STEP 3 trial demonstrated even higher results at approximately 16% when combined with intensive behavioural therapy. Mounjaro's SURMOUNT-1 trial showed impressive outcomes too, though direct comparisons aren't appropriate due to different trial designs and patient populations.
The 1.7mg dose represents a crucial transition point in Wegovy's escalation schedule, occurring during weeks 13-16 before reaching the 2.4mg maintenance dose. At this stage, many patients report increased satiety and reduced food cravings as the medication approaches its full therapeutic effect. Both Wegovy and Mounjaro are available from EverydayMeds through our GPhC-registered pharmacy (#9012878), and your prescriber can help determine which treatment aligns with your specific health profile and weight management goals.
Wegovy 1.7mg Pricing vs Mounjaro: UK Cost Comparison
Understanding the cost implications when comparing 1.7mg Wegovy to Mounjaro helps with long-term treatment planning. Our Wegovy 1.7mg pen costs £139.99, representing excellent value as you approach the maintenance phase. New customers can apply code FIRST40 at checkout, whilst returning customers benefit from DOSE25 for continued savings. For seamless progression to maintenance, our Elevate Duo bundle (1.7mg + 2.4mg) provides both doses for £369.99, ensuring uninterrupted treatment continuity.
The Consistency 1.7mg bundle offers two pens for £309.99, ideal if you need to remain at this dose longer than the standard four-week period. This flexibility proves particularly valuable when comparing treatment options, as some patients require extended time at intermediate doses. Both prescription-only medicines require ongoing monthly costs, making bundle options attractive for budget planning and ensuring consistent medication supply without repeated ordering.
STEP Trial Results: Evidence Behind Wegovy 1.7mg to Mounjaro Comparison
The STEP clinical programme provides robust evidence supporting Wegovy's efficacy in weight management. STEP 1 demonstrated that patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved sustained weight loss over 68 weeks. STEP 5 extended these findings, showing approximately clinically studied weight loss maintained at two years, indicating long-term effectiveness.
Most significantly, the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events among participants using Wegovy. This evidence strengthens the case for semaglutide-based treatment when comparing 1.7mg Wegovy to Mounjaro options, particularly for patients with existing cardiovascular risk factors requiring comprehensive weight management support.
How Wegovy 1.7mg Works: Mechanism vs Mounjaro
Understanding the mechanistic differences helps explain why some patients prefer Wegovy 1.7mg to Mounjaro when comparing treatment options. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, reducing appetite and promoting satiety after smaller meals. This single-target approach provides reliable appetite suppression by working on brain appetite centres, often reducing food cravings significantly. Mounjaro (tirzepatide) operates as a dual GIP and GLP-1 receptor agonist, targeting two hormone pathways simultaneously. Both mechanisms prove effective, but individual responses vary, making prescriber guidance essential when choosing between treatments. The weekly injection schedule remains consistent for both medications, offering convenient once-weekly dosing that fits easily into most lifestyles.
Ordering Wegovy 1.7mg: Simple UK Process vs Mounjaro Access
Accessing Wegovy 1.7mg through EverydayMeds involves a straightforward three-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review applications within three working days (or 24 hours with express service), ensuring thorough evaluation before approving treatment. Once approved, we dispatch your medication via next-day delivery using specialist cold-chain transport to maintain optimal storage conditions. This prescription-only medicine requires proper medical oversight, which our GPhC-registered pharmacy provides alongside comprehensive patient support. The same streamlined process applies whether you're comparing Wegovy 1.7mg to Mounjaro or switching between treatments, with our clinical team available for guidance throughout your weight management journey.
Storage Advantages: Wegovy 1.7mg vs Mounjaro Practical Benefits
Storage considerations often influence treatment choice when comparing 1.7mg Wegovy to Mounjaro for practical lifestyle fit. Wegovy offers superior storage flexibility, remaining stable for up to six weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This advantage proves invaluable for frequent travellers or those with unpredictable schedules requiring medication portability. The FlexTouch pen design provides intuitive operation with clear dose indication, whilst the mandatory dose escalation from 0.25mg through 0.5mg, 1mg, and 1.7mg to 2.4mg maintenance ensures optimal tolerability. Both treatments require refrigeration between 2-8°C before first use, but Wegovy's extended room temperature stability offers greater lifestyle accommodation for active patients managing demanding schedules.
Advanced Comparison: Why Choose Wegovy 1.7mg Over Mounjaro
Several factors differentiate Wegovy 1.7mg from Mounjaro beyond basic efficacy comparisons. The single-target GLP-1 approach may suit patients who prefer established mechanisms with extensive clinical experience, as semaglutide has longer real-world usage data supporting its safety profile. Additionally, the storage advantages and pen design often appeal to patients prioritising convenience and travel flexibility. Some patients report more predictable appetite suppression with the GLP-1-only mechanism compared to dual receptor activation.
Cost considerations also favour Wegovy in many scenarios, with our competitive pricing at £139.99 for 1.7mg representing excellent value during the dose escalation phase. The established dosing schedule and clear progression pathway from initiation through maintenance provides structured treatment planning that many patients and prescribers appreciate when implementing long-term weight management strategies.
Next Steps: Accessing Wegovy 1.7mg Through EverydayMeds
Ready to progress with Wegovy 1.7mg after comparing it to Mounjaro? New customers can secure their prescription using code FIRST40 at checkout, whilst returning patients benefit from DOSE25 for continued savings on their weight management journey. Our clinical assessment ensures appropriate prescribing, with express review available for faster treatment initiation when medically suitable. Both Wegovy and Mounjaro remain available through our platform, giving you choice and flexibility as your treatment needs evolve. Visit our Wegovy 1.7mg product page to begin your clinical assessment and take the next step in your weight management journey with confidence and professional medical support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
